Key result
VKORC1 and CYP2C9 genetic polymorphisms, along with clinical factors, explained 57.89% and 56.97% of the variation for mean weekly and stable mean weekly warfarin dose, respectively.
Population
711 patients starting warfarin
Design
Cohort
Follow-up
6 months
Authors
Loading...
May refine warfarin initiation via genotyping; leaves open outcome benefits in prospective trials.
Cohort (n=711)
VKORC1 and CYP2C9 genetic polymorphisms, along with clinical factors, are the primary determinants of both initial and stable warfarin dosing requirements.
Bourgeois et al. (2016) conducted a cohort in Patients starting warfarin (n=711). Genetic and clinical factors (VKORC1, CYP2C9, age, height, weight, etc.) was evaluated on Mean weekly warfarin dose (MWD), stable mean weekly dose (SMWD) and international normalised ratio (INR) > 4 during the first week. VKORC1 and CYP2C9 genetic polymorphisms, along with clinical factors, explained 57.89% and 56.97% of the variation for mean weekly and stable mean weekly warfarin dose, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: